Curevac N.V. (CVAC) has released an update.
CureVac N.V., a leader in mRNA technology, has initiated a Phase 1/2 study for a pre-pandemic H5N1 avian influenza vaccine, developed in partnership with GSK. The study aims to evaluate the safety and immune response of the vaccine candidate, which utilizes CureVac’s second-generation mRNA platform. This effort is part of their ongoing collaboration to prepare for potential future pandemics.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
